Market Cap 19.43B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 8.28
Forward PE 8.86
Profit Margin 16.87%
Debt to Equity Ratio 0.27
Volume 977,000
Avg Vol 1,400,858
Day's Range N/A - N/A
Shares Out 146.53M
Stochastic %K 85%
Beta 0.14
Analysts Sell
Price Target $169.45

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: (617) 679-2000
Address:
225 Binney Street, Cambridge, United States
benet
benet Jul. 25 at 3:26 PM
0 · Reply
benet
benet Jul. 25 at 3:20 PM
$BIIB zurzavae received positive opinion from CHMP. Existing revenues in the tens of millions. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2025
0 · Reply
theDIOyears
theDIOyears Jul. 24 at 12:53 AM
$BIIB Have yall listened to their Jun 10, 2025 Goldman sachs CC? They talk about the recent blood-based FDA approved test and how sub-Q injection can aid in triaging potential patients for treatment. "Quest plans to make the test available to physicians and biopharmaceutical collaborators later this summer. The test is the first blood-based IVD test cleared by the U.S. Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. It is designed to aid the clinical assessment of Alzheimer's disease in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline." https://ir.questdiagnostics.com/press-releases/press-release-details/2025/Quest-Diagnostics-to-Offer-FDA-Cleared-Fujirebio-Blood-Test-for-Alzheimers-Disease/default.aspx
0 · Reply
AriVe
AriVe Jul. 23 at 10:13 PM
$BIIB Today, the driving force behind The Golden Earring, George Kooymans, passed away. Who doesn't know him from Radar Love, Twilight Zone, and When the Lady Smiles? George died from complications of the debilitating disease ALS. One of the best singers and songwriters the Netherlands has ever produced, R.I.P. George, and thank you for your music. This was his last performance. https://www.youtube.com/watch?v=of0Je7XYSBI&list=RDof0Je7XYSBI&start_radio=1
1 · Reply
Molllz_smartmoney
Molllz_smartmoney Jul. 21 at 6:55 PM
Unusual large options flow detected for $BIIB! August 15 strike at 125, just before earnings on July 31. A high-stakes move to watch on ER! #RiskyERplay
0 · Reply
FractionalShareWhale
FractionalShareWhale Jul. 21 at 6:19 PM
$BIIB adding here
0 · Reply
traderjoe90
traderjoe90 Jul. 21 at 6:17 PM
$BIIB playa layin wood in Aug 125 calls. $2.1M. Bottom feeding or protecting a large short position.
0 · Reply
theDIOyears
theDIOyears Jul. 21 at 6:05 PM
$BIIB July 31st, Q2 2025 earnings. August 31st LEQEMBI sub-Q PDUFA.
0 · Reply
kellysmith1
kellysmith1 Jul. 21 at 3:20 PM
$BIIB whoa!!!!!
0 · Reply
degearea
degearea Jul. 21 at 3:19 PM
$BIIB goddamn this pig. On verge of ditching it.
1 · Reply
Latest News on BIIB
Biogen to invest $2 billion more in North Carolina

Jul 21, 2025, 7:41 AM EDT - 4 days ago

Biogen to invest $2 billion more in North Carolina


Biogen: Investors Are Missing The Bigger Picture

Jun 22, 2025, 10:27 PM EDT - 4 weeks ago

Biogen: Investors Are Missing The Bigger Picture


Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript

May 1, 2025, 11:38 AM EDT - 3 months ago

Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript


Biogen Analysts Lower Their Forecasts After Q4 Results

Feb 13, 2025, 9:03 AM EST - 5 months ago

Biogen Analysts Lower Their Forecasts After Q4 Results


Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 12:41 PM EST - 5 months ago

Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript


Drugmaker Biogen forecasts 2025 profit below expectations

Feb 12, 2025, 6:47 AM EST - 5 months ago

Drugmaker Biogen forecasts 2025 profit below expectations


Europe to review safety data for Eisai-Biogen Alzheimer's drug

Jan 31, 2025, 6:46 AM EST - 6 months ago

Europe to review safety data for Eisai-Biogen Alzheimer's drug


Sage rejects Biogen's $469 million takeover offer

Jan 27, 2025, 9:28 AM EST - 6 months ago

Sage rejects Biogen's $469 million takeover offer


benet
benet Jul. 25 at 3:26 PM
0 · Reply
benet
benet Jul. 25 at 3:20 PM
$BIIB zurzavae received positive opinion from CHMP. Existing revenues in the tens of millions. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2025
0 · Reply
theDIOyears
theDIOyears Jul. 24 at 12:53 AM
$BIIB Have yall listened to their Jun 10, 2025 Goldman sachs CC? They talk about the recent blood-based FDA approved test and how sub-Q injection can aid in triaging potential patients for treatment. "Quest plans to make the test available to physicians and biopharmaceutical collaborators later this summer. The test is the first blood-based IVD test cleared by the U.S. Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. It is designed to aid the clinical assessment of Alzheimer's disease in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline." https://ir.questdiagnostics.com/press-releases/press-release-details/2025/Quest-Diagnostics-to-Offer-FDA-Cleared-Fujirebio-Blood-Test-for-Alzheimers-Disease/default.aspx
0 · Reply
AriVe
AriVe Jul. 23 at 10:13 PM
$BIIB Today, the driving force behind The Golden Earring, George Kooymans, passed away. Who doesn't know him from Radar Love, Twilight Zone, and When the Lady Smiles? George died from complications of the debilitating disease ALS. One of the best singers and songwriters the Netherlands has ever produced, R.I.P. George, and thank you for your music. This was his last performance. https://www.youtube.com/watch?v=of0Je7XYSBI&list=RDof0Je7XYSBI&start_radio=1
1 · Reply
Molllz_smartmoney
Molllz_smartmoney Jul. 21 at 6:55 PM
Unusual large options flow detected for $BIIB! August 15 strike at 125, just before earnings on July 31. A high-stakes move to watch on ER! #RiskyERplay
0 · Reply
FractionalShareWhale
FractionalShareWhale Jul. 21 at 6:19 PM
$BIIB adding here
0 · Reply
traderjoe90
traderjoe90 Jul. 21 at 6:17 PM
$BIIB playa layin wood in Aug 125 calls. $2.1M. Bottom feeding or protecting a large short position.
0 · Reply
theDIOyears
theDIOyears Jul. 21 at 6:05 PM
$BIIB July 31st, Q2 2025 earnings. August 31st LEQEMBI sub-Q PDUFA.
0 · Reply
kellysmith1
kellysmith1 Jul. 21 at 3:20 PM
$BIIB whoa!!!!!
0 · Reply
degearea
degearea Jul. 21 at 3:19 PM
$BIIB goddamn this pig. On verge of ditching it.
1 · Reply
DonCorleone77
DonCorleone77 Jul. 21 at 11:34 AM
$BIIB Biogen plans to invest $2B in manufacturing footprint in North Carolina's RTP
1 · Reply
Quantumup
Quantumup Jul. 21 at 11:07 AM
Stifel $ALKS Buy-$42: "We are reiterating our Buy rating on $ALKS on the back of positive top-line data for ALKS2680/"Alixorexton" in Narcolepsy Type-1. Bottom line: this study was widely expected to succeed given prior ph1b data in NT1 and broader support via Takeda. Even still, the results here look clearly positive with many key clinical endpoints hitting statistical significance at all doses, with the exception of cataplexy attacks which "numerically improved" at all doses and only hit a p-value at the mid-dose (we await details, but probably a powering/variability issue). On safety, the disclosure was fairly high level, but 95% of patients who participated in the trial entered the OLE which is always encouraging. The PR specifically noted no treatment-related signals in hepatic/renal parameters, vital signs or ophthalmic exams, but we'll need to wait for full data to see if there were any mild visual AEs at all -- we remain generally unconcerned though." $TAK $BIIB $AXSM JAZZ $CNTA
0 · Reply
Quantumup
Quantumup Jul. 18 at 3:27 PM
Mizuho reiterated $AXSM Outperform-$210: $ALKS $ACAD OTSKF $AVXL $BIIB Mizuho said in its note to investors:
1 · Reply
jcomicon
jcomicon Jul. 17 at 12:12 PM
$BIIB I don’t a position or follow this company actively. What caused them to plummet over recent years?
1 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 16 at 11:29 PM
I’ll invest in $AVXL when they make clear they have a pathway outside of the EMA. The FDA is much more valuable and they don’t have to negotiate for reimbursement with each country. $TLSA excites me moreso at these valuation levels but Anavex isn’t dead to me like $INMB , $SAVA , and $BIIB 💪
6 · Reply
Ambro
Ambro Jul. 16 at 4:22 PM
$BIIB double bottom inbound imo...
0 · Reply
jozef56
jozef56 Jul. 15 at 1:57 PM
$ALKS $BIIB $TAK $AXSM $CNTA also golman sacks has his own agenda ...never trust analysts
0 · Reply
Quantumup
Quantumup Jul. 15 at 1:18 PM
Goldman Sachs🏁 $ALKS But/$43. $BIIB $TAK $AXSM JAZZ $CNTA Goldman Sachs said in its initiation report:
0 · Reply
Quantumup
Quantumup Jul. 14 at 4:24 PM
UBS reiterated $PTCT Buy-$71 after they hosted a medical geneticist and professor of pediatrics who is an expert on PKU and treats~320 patients. $BMRN $SRPT $JNJ $BIIB NVS RHHBY LRMR RARE VRTX EWTX CAPR #KOL UBS added, "Our discussion focused on the treatment paradigm in PKU with current management options (low-Phe diet, Kuvan/sapropterin, Palnynziq) as well as $PTCT's sepiapterin (recently approved in Europe as Sephience, US FDA PDUFA 7/29). Overall, we think the call was highly supportive of a strong potential launch for $PTCT's sepiapterin. UBS went on to give Their Key Takeaways from the Expert Call (In IMAGE Below):
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 14 at 9:17 AM
$BIIB https://finance.yahoo.com/news/amyotrophic-lateral-sclerosis-als-market-080100838.html
0 · Reply
buyandsold
buyandsold Jul. 13 at 5:06 PM
I expect $BIIB to offer 25 cents more cash and the same CVR terms as $SUPN to take $SAGE I think that if the try to value the CVR and do all cash then $SAGE management hates them so much they will say the CVR is worth more and reject. If $BIIB does not make an offer this weekend my expectation will be much reduced as time is really rather short to make a move.
0 · Reply
IN0V8
IN0V8 Jul. 11 at 4:57 PM
$BIIB HSBC raises target price to $144 from $121
0 · Reply